A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is being conducted to compare the safety and effectiveness of the investigational
medication, LdT (Telbivudine) with Lamivudine, a drug currently approved by the US, European
and Asian Health Authorities for the treatment of hepatitis B infection. The results for
patients taking LdT will be compared to results for patients taking Lamivudine.